Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience.

[1]  F. Pouwer,et al.  Continuous intraperitoneal insulin infusion in patients with ‘brittle’ diabetes: favourable effects on glycaemic control and hospital stay , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[2]  E. Renard,et al.  Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. , 2002, Diabetes & metabolism.

[3]  E. Renard,et al.  Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. , 2001, Diabetes & metabolism.

[4]  V. Melki,et al.  Assessment of in vivo stability of a new insulin preparation for implantable insulin pumps. A randomized multicenter prospective trial. EVADIAC Group. Evaluation Dans le diabète du Traitement par Implants Actifs. , 1999, Diabetes care.

[5]  V. Lassmann-Vague,et al.  Local Adverse Events Associated With Long-Term Treatment by Implantable Insulin Pumps: The French EVADIAC Study Group experience , 1998, Diabetes Care.

[6]  R. Udelsman,et al.  Implanted programmable insulin pumps: one hundred fifty-three patient years of surgical experience. , 1997, Surgery.

[7]  A. Giobbie-Hurder,et al.  Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. , 1996, JAMA.

[8]  C Jaffiol,et al.  Insulin Underdelivery From Implanted Pumps Using Peritoneal Route: Determinant role of insulin pump compatibility , 1996, Diabetes Care.

[9]  E. Renard,et al.  Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study , 1995, Diabetes Care.

[10]  E. Renard,et al.  Catheter Complications Associated With Implantable Systems for Peritoneal Insulin Delivery: An analysis of frequency, predisposing factors, and obstructing materials , 1995, Diabetes Care.

[11]  N. Jeandidier,et al.  French multicentre experience of implantable insulin pumps , 1994, The Lancet.

[12]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[13]  D. Nathan,et al.  Clinical Trial of Programmable Implantable Insulin Pump For Type I Diabetes , 1992, Diabetes Care.

[14]  H. Pitt,et al.  A preliminary trial of the programmable implantable medication system for insulin delivery. , 1989, The New England journal of medicine.

[15]  C. Saudek,et al.  Stable Insulin Preparation for Implanted Insulin Pumps: Laboratory and Animal Trials , 1987, Diabetes.

[16]  N. Jeandidier,et al.  Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. , 2002, Diabetes care.

[17]  H Gin,et al.  Clinical evaluation of a newly designed compliant side port catheter for an insulin implantable pump: the EVADIAC experience. Evaluation dans le Diabete du Traitement par Implants Actifs. , 2001, Diabetes care.